evidence to recommendations table · the recommendation applies to specific contexts, in specific...

29
Page 1 of 29 Evidence to Recommendations Table Question: Should the currently available whole cell, killed Oral cholera vaccines (OCVs) be recommended for use among persons ≥1 year old (Shanchol/Euvichol/mORCVax) or ≥ 2 years old (Dukoral), including pregnant women in different cholera endemic, epidemic/outbreak and humanitarian emergency settings? Population: Individuals in different cholera endemic, epidemic/outbreak and humanitarian emergency settings. Intervention: Killed, whole-cell oral cholera vaccines Comparison: Placebo/no vaccination/other prevention and control measures (e.g. WASH) Outcome: Cases of cholera Background: Cholera, an acute watery diarrheal disease, caused by toxigenic strains of the bacterium Vibrio cholerae O1 and O139, causes an estimated over 2.9 million cases and over 95,000 deaths annually in cholera endemic countries alone and frequent epidemics in other settings with poor water and sanitation infrastructure. Global estimates range from 1.4 4.8 million cases and 28,000 142,000 deaths every year. The disease is characterized by acute onset watery diarrhea leading to rapid dehydration and death, if not promptly treated with fluid replacement and antibiotics for severe cases. Pregnant women are especially vulnerable from the dehydrating effects of cholera. OCVs have been available since the 1990s and have been recommended previously by WHO (most recent position statement of 2010). Since 2010, large scale epidemics and surges in endemic cholera have continued to occur and have been compounded by multiple humanitarian emergency situations. In 2013, a global oral cholera vaccine stockpile was established. Several additional studies and evaluations have been conducted of OCV use in different endemic, outbreak and humanitarian emergency settings. Additional data is now available to review evidence for recommendations. CRITERIA JUDGEMENTS RESEARCH EVIDENCE ADDITIONAL INFORMATION PROBLEM Is the problem a priority? No Probably No Uncertain Probably Yes Yes Varies Cholera remains a significant public health problem globally. Global estimates range from 1.4 4.8 million cases and 28,000 142,000 The global burden has significantly increased as a result of humanitarian emergencies (conflict situations, natural disasters and

Upload: others

Post on 04-Oct-2020

1 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: Evidence to Recommendations Table · The recommendation applies to specific contexts, in specific (sub) populations and in conjunction with other prevention and control measures

Page 1 of 29

Evidence to Recommendations Table

Question: Should the currently available whole cell, killed Oral cholera vaccines (OCVs) be recommended for use among persons ≥1 year old (Shanchol/Euvichol/mORCVax) or ≥ 2 years old (Dukoral), including pregnant women in different cholera endemic, epidemic/outbreak and humanitarian emergency settings? Population: Individuals in different cholera endemic, epidemic/outbreak and humanitarian emergency settings. Intervention: Killed, whole-cell oral cholera vaccines Comparison: Placebo/no vaccination/other prevention and control measures (e.g. WASH) Outcome: Cases of cholera Background: Cholera, an acute watery diarrheal disease, caused by toxigenic strains of the bacterium Vibrio cholerae O1 and O139, causes an estimated over 2.9 million cases and over 95,000 deaths annually in cholera endemic countries alone and frequent epidemics in other settings with poor water and sanitation infrastructure. Global estimates range from 1.4 –4.8 million cases and 28,000 – 142,000 deaths every year. The disease is characterized by acute onset watery diarrhea leading to rapid dehydration and death, if not promptly treated with fluid replacement and antibiotics for severe cases. Pregnant women are especially vulnerable from the dehydrating effects of cholera. OCVs have been available since the 1990s and have been recommended previously by WHO (most recent position statement of 2010). Since 2010, large scale epidemics and surges in endemic cholera have continued to occur and have been compounded by multiple humanitarian emergency situations. In 2013, a global oral cholera vaccine stockpile was established. Several additional studies and evaluations have been conducted of OCV use in different endemic, outbreak and humanitarian emergency settings. Additional data is now available to review evidence for recommendations. CRITERIA JUDGEMENTS RESEARCH EVIDENCE ADDITIONAL INFORMATION

PROB

LEM

Is the problem a priority?

No Probably No

Uncertain Probably Yes

Yes Varies

Cholera remains a significant public health problem globally. Global estimates range from 1.4 –4.8 million cases and 28,000 – 142,000

The global burden has significantly increased as a result of humanitarian emergencies (conflict situations, natural disasters and

Page 2: Evidence to Recommendations Table · The recommendation applies to specific contexts, in specific (sub) populations and in conjunction with other prevention and control measures

Page 2 of 29

deaths every year. An estimated 2.9 million cases of cholera annually in 69 cholera endemic countries and 95,000 deaths during 2008–2012. Pregnant women are especially susceptible to adverse outcomes for themselves and the fetuses as a result of rapid dehydration. Cholera most often occurs among impoverished populations with limited access to health care resources.

environmental factors such as the El Nino phenomenon).

Are a large number of people affected?

No Probably No

Uncertain Probably Yes

Yes Varies

Global estimates range from 1.4 –4.8 million cases and 28,000 – 142,000 deaths every year. An estimated 2.9 million cases of cholera annually in 69 cholera endemic countries and 95,000 deaths during 2008–2012. In 2015, over 172,454 cases and 1,304 deaths were reported to the WHO by 42 countries with an overall case-fatality rate (CFR) of 0.8% (several countries reported high case fatality rates).

The reported numbers are largely underreported due to several factors – inadequate surveillance, fear of impact on trade and tourism etc.

BEN

EFIT

S &

HAR

MS

OF T

HE

OPTI

ONS

Are the desirable anticipated effects large?

No Probably No

Uncertain Probably Yes

Yes Varies

The vaccines have been shown to be efficacious and effective in multiple settings. Additional data showing herd protection effects is also available. However, data on the actual impact on disease transmission is limited.

The impact is dependent on factors such as vaccine coverage. Data on coverage in most settings show that vaccination campaigns have been feasible and acceptable.

Are the undesirable anticipated effects small?

No Probably No

Uncertain Probably Yes

Yes Varies

Safety of the vaccines has been demonstrated in several different settings.

Page 3: Evidence to Recommendations Table · The recommendation applies to specific contexts, in specific (sub) populations and in conjunction with other prevention and control measures

Page 3 of 29

What is the overall certainty of this evidence?

No included studies Very low Low Moderate High

28

Moderate to high level of evidence. In addition to the 28 studies included in the systematic review, there are several other evaluations and observational studies that corroborate these findings.

VALU

ES

How certain is the relative importance of the desirable and undesirable outcomes?

Important uncertainty

or variability

Possibly important

uncertainty or

variability

Probably no

important uncertainty

or variability

No important

uncertainty or

variability

No known undesirable outcomes

Vaccines have been shown to be safe and effective in multiple settings. No major adverse events have been demonstrated.

Are the desirable effects large relative to undesirable effects?

No Probably No

Uncertain Probably Yes

Yes Varies

RESO

URCE

USE

Are the resources required small?

No Probably No

Uncertain Probably Yes

Yes Varies

A global OCV stockpile was established in 2013 and is financially supported by Gavi, the Vaccine Alliance. Gavi also provides funding for operational costs of vaccination campaigns. The resources required to conduct vaccination activities have varied based on the setting.

Vaccines are available through the Gavi-supported stockpile. Additionally, manufacturers are working to reduce the cost of vaccine to a more affordable pricing.

Is the incremental cost small relative to the net benefits?

No Probably No

Uncertain Probably Yes

Yes Varies

Several costing and cost-effectiveness studies have showed that cholera vaccination is cost-effective at the current vaccine pricing in high burden settings.

There is emphasis also on ensuring the OCVs are integrated into overall country and regional level cholera control plans.

Page 4: Evidence to Recommendations Table · The recommendation applies to specific contexts, in specific (sub) populations and in conjunction with other prevention and control measures

Page 4 of 29

EQUI

TY

What would be the impact on health inequities?

Increased Probably increased

Uncertain Probably reduced

Reduced Varies

This disease affects mainly populations in poor-resource settings with limited clean water, sanitation and hygiene. The intervention would reduce health-inequities across populations.

ACCE

PTAB

ILIT

Y

Is the option acceptable to key stakeholders?

No Probably No

Uncertain Probably Yes

Yes Varies

Since the establishment of the OCV stockpile in 2013, over 7 million doses have been used in over 14 countries in multiple endemic, outbreak, and humanitarian emergency situations, and requests have been made by country-level stakeholders to the International Coordinating Group (ICG). Therefore, it is assumed that the option is acceptable to key stakeholders.

Which option is acceptable to target group? Intervention Comparison

Both Neither Unclear

Multiple evaluations of vaccine coverage and knowledge, attitudes and practices have been conducted which have shown that vaccination has been feasible and acceptable in multiple settings.

FEAS

IBIL

ITY

Is the option feasible to implement?

No Probably No

Uncertain Probably Yes

Yes Varies

The option will likely be feasible to implement in most settings, though limited access in the context of natural disasters or armed conflict may impede immediate implementation.

Balance of consequences

Undesirable consequences

clearly outweigh desirable consequences

in most settings

Undesirable consequences probably

outweigh desirable consequences

in most settings

The balance between desirable and undesirable

consequences is closely balanced or

uncertain

Desirable consequences probably outweigh

undesirable consequences

in most settings

Desirable consequences clearly outweigh

undesirable consequences in most settings

Page 5: Evidence to Recommendations Table · The recommendation applies to specific contexts, in specific (sub) populations and in conjunction with other prevention and control measures

Page 5 of 29

Type of recommendation

We recommend against the option

We suggest considering the option

Only in the context of rigorous research

Only with targeted monitoring and evaluation

Only in specific contexts

We recommend the option

The recommendation applies to specific contexts, in specific (sub)

populations and in conjunction with other prevention and control

measures.

Recommendation

Given the current availability of prequalified whole-cell, killed, oral cholera vaccines (OCVs) and data on their safety, efficacy, field effectiveness, feasibility, impact and acceptability in cholera-affected populations, these vaccines should be used in areas with endemic cholera, in humanitarian crisis with high risk of cholera and during cholera outbreaks, in conjunction with other cholera prevention and control strategies such as appropriate case management, WaSH interventions, surveillance and community mobilization. Based on available evidence, there are considerable benefits and very few risks for including pregnant women in OCV vaccination campaigns.

Implementation considerations

Mass vaccination campaigns are usually the most practical option for delivering oral cholera vaccines. Schools, religious institutions and other community settings can be appropriate venues for vaccination campaigns using fixed sites. Outreach activities can also be organized. Incorporating cholera vaccination with other vaccination activities can be an alternative or complementary strategy to mass campaigns.

Planning for campaigns should be done in a timely manner so vaccines can be used as soon as they arrive in country. It’s beneficial to use vaccines as early as possible in outbreak situations.

Monitoring and evaluation Monitoring and evaluation activities should be conducted to document experiences and understanding vaccine impact.

These are also critical to be done if newer vaccines or newer delivery strategies are implemented.

Page 6: Evidence to Recommendations Table · The recommendation applies to specific contexts, in specific (sub) populations and in conjunction with other prevention and control measures

Page 6 of 29

Research priorities It is important to perform systematic economic analyses to measure intervention cost, cost effectiveness and cost benefit in different settings where campaigns have been conducted.

Additional research is needed to better inform number of doses, optimal dosing interval (dose spacing) and issues related to duration of protection in different settings. More information is needed on the effectiveness in children 1—5 years old.

Further assessment of herd protection is needed.

There is a need to further work on methodologies to measure the impact of vaccination by better defining relevant and meaningful comparison groups and identify standardized indicators across geographies and settings.

Alternative delivery strategies such as self-administration, outside-the-cold-chain (CTC / ECTC), linking OCV with other health interventions should be further evaluated in a large variety of settings.

More information is needed on co-administration of OCV with other vaccines, especially with oral vaccines such as oral polio vaccine and rotavirus vaccine.

Page 7: Evidence to Recommendations Table · The recommendation applies to specific contexts, in specific (sub) populations and in conjunction with other prevention and control measures

Page

7 o

f 29

A

pp

en

dix

3:

Sum

mar

y o

f Ev

ide

nce

GR

AD

E Ta

ble

s

Safe

ty in

gen

eral

po

pu

lati

on

P

op

ula

tio

n: N

on-p

regn

ant a

dults

and

chi

ldre

n ≥

1 ye

ar o

ld (S

hanc

hol/E

uvic

hol/m

ORC

Vax)

or ≥

2 y

ears

old

(D

ukor

al)

Inte

rven

tio

n: 2

dos

es o

f the

cur

rent

ly a

vaila

ble

kille

d, w

hole

-cel

l ora

l cho

lera

vac

cine

s (O

CVs)

C

om

par

iso

n: P

lace

bo o

r no

vacc

ine/

oth

er p

reve

ntio

n an

d co

ntro

l mea

sure

s (e.

g. w

ater

, san

itatio

n an

d hy

gien

e (W

ASH)

) O

utc

om

e: S

erio

us A

dver

se E

vent

s Fol

low

ing

Imm

uniza

tion

Wha

t is t

he e

vide

nce

that

the

curr

ently

ava

ilabl

e ki

lled,

who

le-c

ell O

CVs a

re sa

fe a

mon

g no

n-pr

egna

nt

indi

vidu

als (

Duko

ral ≥

2 y

ears

old

, Sha

ncho

l/Eu

vich

ol/m

ORC

Vax

≥ 1

year

old

s)?

Ra

ting

Adju

stm

ent t

o Ra

ting

Qua

lity

of

Evid

ence

No.

of s

tudi

es/s

tart

ing

ratin

g 10

RCT

1 4

Fact

ors

decr

easin

g co

nfid

ence

Lim

itatio

n in

stud

y de

sign

No

serio

us

0 In

cons

isten

cy

No

serio

us

0 In

dire

ctne

ss

No

serio

us

0 Im

prec

ision

N

o se

rious

0

Publ

icat

ion

Bias

N

o se

rious

0

Fact

ors

Incr

easin

g Co

nfid

ence

Larg

e ef

fect

N

ot a

pplic

able

0

Dose

-res

pons

e N

ot a

pplic

able

0

Anta

goni

stic

bia

s and

co

nfou

ndin

g N

ot a

pplic

able

0

Fina

l num

eric

al ra

ting

of q

ualit

y of

evi

denc

e 4

Sum

mar

y of

Fin

ding

s

Stat

emen

t on

qual

ity o

f evi

denc

e

Evid

ence

supp

orts

a

high

leve

l of c

onfid

ence

th

at th

e tr

ue e

ffect

lies

cl

ose

to th

at

of th

e es

timat

e of

the

effe

ct o

n th

e he

alth

ou

tcom

e.

Conc

lusio

n

High

leve

l of s

cien

tific

ev

iden

ce th

at th

e ris

k of

se

rious

adv

erse

eve

nts

follo

win

g im

mun

izatio

n w

hen

usin

g th

e cu

rren

tly li

cens

ed O

CVs

is lo

w.

1 In a

dditi

on to

the

rand

omize

d co

ntro

lled

tria

ls, se

vera

l fie

ld st

udie

s (fie

ld e

ffect

iven

ess a

nd c

over

age

surv

eys)

hav

e ev

alua

ted

the

occu

rren

ce o

f adv

erse

eve

nts a

nd th

e fin

ding

s of t

hese

stud

ies s

uppo

rt th

e hi

gh le

vel o

f evi

denc

e fr

om th

e ra

ndom

ized

cont

rolle

d tr

ials

used

for g

radi

ng fo

r saf

ety

outc

omes

.

Page 8: Evidence to Recommendations Table · The recommendation applies to specific contexts, in specific (sub) populations and in conjunction with other prevention and control measures

Page

8 o

f 29

R

efe

ren

ces

1.

Co

ncha

A e

t al.

Safe

ty a

nd im

mun

ogen

icity

of o

ral k

illed

who

le c

ell r

ecom

bina

nt B

subu

nit c

hole

ra

vacc

ine

in B

arra

nqui

lla, C

olom

bia.

Bul

l Pan

Am

Hea

lth O

rgan

199

5; 2

9(4)

:312

-321

. 2.

Tr

ach

DD e

t al.

Inve

stig

atio

ns in

to th

e sa

fety

and

imm

unog

enic

ity o

f a k

illed

ora

l cho

lera

vac

cine

de

velo

ped

in V

iet N

am. B

ull P

an A

m H

ealth

Org

an 2

002;

80(

1):2

-8.

3.

Anh

DD e

t al.

Safe

ty a

nd im

mun

ogen

icity

of a

refo

rmul

ated

Vie

tnam

ese

biva

lent

kill

ed, w

hole

-cel

l, or

al c

hole

ra v

acci

ne in

adu

lts. V

acci

ne 2

007;

25(

6):1

149-

1155

. 4.

M

ahan

abal

is D

et a

l. A

Rand

omize

d, P

lace

bo-C

ontr

olle

d Tr

ial o

f the

Biv

alen

t Kill

ed, W

hole

-Cel

l, O

ral

Chol

era

Vacc

ine

in A

dults

and

Chi

ldre

n in

a C

hole

ra E

ndem

ic A

rea

in K

olka

ta, I

ndia

Plo

sOne

200

8;

3(6)

: e23

23.

5.

Sur D

et a

l. Ef

ficac

y an

d sa

fety

of a

mod

ified

kill

ed-w

hole

-cel

l ora

l cho

lera

vac

cine

in In

dia:

an

inte

rim a

naly

sis o

f a c

lust

er-r

ando

mise

d, d

oubl

e-bl

ind,

pla

cebo

-con

trol

led

tria

l. La

ncet

200

9; 3

74:

1694

-170

2.

6.

Saha

A e

t al.

Safe

ty a

nd im

mun

ogen

icity

stud

y of

a k

illed

biv

alen

t (O

1 an

d O

139)

who

le-c

ell o

ral

chol

era

vacc

ine

Shan

chol

, in

Bang

lade

shi a

dults

and

chi

ldre

n as

you

ng a

s 1 y

ear o

f age

. Vac

cine

20

11; 2

9(46

): 82

85-8

295.

7.

Q

adri

F et

al.

Feas

ibili

ty a

nd e

ffect

iven

ess o

f ora

l cho

lera

vac

cine

in a

n ur

ban

ende

mic

sett

ing

in

Bang

lade

sh: a

clu

ster

rand

omise

d op

en-la

bel t

rial.

Lanc

et 2

015;

386

:136

2-13

71.

8.

Desa

i SN

.et a

l. A

Rand

omize

d, P

lace

bo-C

ontr

olle

d Tr

ial E

valu

atin

g Sa

fety

and

Imm

unog

enic

ity o

f th

e Ki

lled.

Biv

alen

t, W

hole

-Cel

l Ora

l Cho

lera

Vac

cine

in E

thio

pia.

Am

. J. T

rop.

Med

. Hyg

201

5, 9

3(3)

: 52

7–53

3 9.

Ba

ik Y

O e

t al.

A ra

ndom

ized,

non

-infe

riorit

y tr

ial c

ompa

ring

two

biva

lent

kill

ed, w

hole

cel

l, or

al

chol

era

vacc

ines

(Euv

icho

l vs S

hanc

hol)

in th

e Ph

ilipp

ines

. Vac

cine

201

5; 3

3(46

): 63

60-6

365.

10

. Qad

ri et

al.

Effic

acy

of a

Sin

gle-

Dose

, Ina

ctiv

ated

Ora

l Cho

lera

Vac

cine

in B

angl

ades

h. N

Eng

l J M

ed

2016

: 374

: 172

3-32

.

Page 9: Evidence to Recommendations Table · The recommendation applies to specific contexts, in specific (sub) populations and in conjunction with other prevention and control measures

Page

9 o

f 29

Sa

fety

in p

regn

ant

wo

men

P

op

ula

tio

n: P

regn

ant w

omen

In

terv

enti

on

: 1-2

dos

es o

f the

cur

rent

ly a

vaila

ble

kille

d, w

hole

-cel

l ora

l cho

lera

vac

cine

s (O

CVs)

C

om

par

iso

n: P

lace

bo o

r no

vacc

ine/

oth

er p

reve

ntio

n an

d co

ntro

l mea

sure

s (e.

g. W

ASH)

O

utc

om

e: P

regn

ancy

-spe

cific

mat

erna

l/fet

al/n

eona

tal s

erio

us a

dver

se e

vent

s fol

low

ing

imm

uniza

tion

Wha

t is t

he e

vide

nce

that

the

curr

ently

ava

ilabl

e ki

lled,

who

le c

ell O

CVs a

re sa

fe in

pre

gnan

cy?

Ra

ting

Adju

stm

ent t

o Ra

ting

Qua

lity

of

Evid

ence

No.

of s

tudi

es/s

tart

ing

ratin

g 1

RCT/

3

Obs

erva

tiona

l 4

Fact

ors

decr

easin

g co

nfid

ence

Lim

itatio

n in

stud

y de

sign

Serio

us1

-2

In

cons

isten

cy

No

serio

us

0 In

dire

ctne

ss

No

serio

us

0 Im

prec

ision

N

o se

rious

0

Publ

icat

ion

Bias

N

o se

rious

0

Fact

ors

Incr

easin

g Co

nfid

ence

Larg

e ef

fect

N

ot a

pplic

able

0

Dose

-res

pons

e N

ot a

pplic

able

0

Anta

goni

stic

bia

s and

co

nfou

ndin

g N

ot a

pplic

able

0

Fina

l num

eric

al ra

ting

of q

ualit

y of

evi

denc

e 2

Sum

mar

y of

Fin

ding

s

Stat

emen

t on

qual

ity o

f evi

denc

e

Evid

ence

supp

orts

a

limite

d le

vel o

f co

nfid

ence

that

the

true

effe

ct li

es c

lose

to

that

of t

he e

stim

ate

of

the

effe

ct o

n th

e he

alth

ou

tcom

e.

Conc

lusio

n

Low

leve

l of s

cien

tific

ev

iden

ce th

at th

e cu

rren

tly li

cens

ed O

CVs

are

safe

for u

se d

urin

g pr

egna

ncy.

1 K

ahn

et a

l., th

e st

udy

was

nes

ted

in a

RCT

, but

not

pow

ered

to d

etec

t a p

rede

fined

a p

riori

risk

(no

spec

ific

sam

ple

size

calc

ulat

ion)

. The

con

trol

gro

up c

ompr

ised

preg

nant

wom

en e

xclu

ded

from

the

tria

l in

the

base

line

asse

ssm

ent

for b

eing

pre

gnan

t (i.e

. non

-ran

dom

ized

wom

en).

Vacc

inat

ed a

nd n

on-v

acci

nate

d pr

egna

nt w

omen

diff

ered

in th

e ba

selin

e ris

k fo

r adv

erse

pre

gnan

cy o

utco

mes

. The

sam

ple

size

was

smal

l (69

exp

osed

and

69

non-

expo

sed

wom

en

incl

uded

in th

e an

alys

is). T

he a

sses

smen

t of t

he p

regn

ancy

out

com

es w

as d

one

retr

ospe

ctiv

ely

and

the

prim

ary

outc

ome

was

any

adv

erse

eve

nt (n

o ad

just

ed e

stim

ates

pro

vide

d fo

r spe

cific

adv

erse

pre

gnan

cy o

utco

mes

).

Page 10: Evidence to Recommendations Table · The recommendation applies to specific contexts, in specific (sub) populations and in conjunction with other prevention and control measures

Page

10

of 2

9

Re

fere

nce

s

1.

Gr

out L

et a

l. Pr

egna

ncy

Out

com

es a

fter

a M

ass V

acci

natio

n Ca

mpa

ign

with

an

Ora

l Cho

lera

Va

ccin

e in

Gui

nea:

A R

etro

spec

tive

Coho

rt. P

LoS

Negl

Tro

p Di

s 201

5. 9

(12)

: e00

0427

4 2.

Ha

shim

R e

t al.

Safe

ty o

f the

reco

mbi

nant

cho

lera

toxi

n B

subu

nit,

kille

d w

hole

-cel

l (rB

S-W

C) o

ral

chol

era

vacc

ine

in p

regn

ancy

. PLo

S Ne

gl T

rop

Dis 2

012;

6(7

): e1

743.

3.

Al

i M e

t al.

Safe

ty o

f a k

illed

ora

l cho

lera

vac

cine

(Sha

ncho

l) in

pre

gnan

t wom

en in

Mal

awi:

an

obse

rvat

iona

l coh

ort s

tudy

. Lan

cet I

nfec

t Dis

2017

. 4.

Kh

an A

I et a

l. Sa

fety

of t

he o

ral c

hole

ra v

acci

ne in

pre

gnan

cy: R

etro

spec

tive

findi

ngs f

rom

a

subg

roup

follo

win

g m

ass v

acci

natio

n ca

mpa

ign

in D

haka

, Ban

glad

esh.

Vac

cine

201

7.

Page 11: Evidence to Recommendations Table · The recommendation applies to specific contexts, in specific (sub) populations and in conjunction with other prevention and control measures

Page

11

of 2

9

Effi

cacy

an

d E

ffec

tive

ne

ss

Po

pu

lati

on

: Non

-pre

gnan

t adu

lts a

nd c

hild

ren

≥ 1

year

old

(Sha

ncho

l/Euv

icho

l/mO

RCVa

x) o

r ≥ 2

yea

rs o

ld

(Duk

oral

) In

terv

enti

on

: 2 d

oses

of t

he c

urre

ntly

ava

ilabl

e ki

lled,

who

le-c

ell o

ral c

hole

ra v

acci

nes (

OCV

s)

Co

mp

aris

on

: Pla

cebo

or n

o va

ccin

e/ o

ther

pre

vent

ion

and

cont

rol m

easu

res (

e.g.

WAS

H)

Ou

tco

me:

Cas

es o

f cho

lera

W

hat i

s the

evi

denc

e fo

r pro

tect

ive

effic

acy

and

effe

ctiv

enes

s aga

inst

cho

lera

(any

seve

rity)

of t

he

curr

ently

ava

ilabl

e ki

lled,

who

le c

ell O

CVs f

ollo

win

g im

mun

izat

ion

amon

g in

divi

dual

s ≥ 1

yea

r old

?

Ratin

g Ad

just

men

t to

Ratin

g

Qua

lity

of

Evid

ence

No.

of s

tudi

es/s

tart

ing

ratin

g 11

RCT

/ 7

obse

rvat

iona

l 4

Fact

ors

decr

easin

g co

nfid

ence

Lim

itatio

n in

stud

y de

sign

No

serio

us

0 In

cons

isten

cy

No

serio

us

0 In

dire

ctne

ss

No

serio

us

0 Im

prec

ision

N

o se

rious

0

Publ

icat

ion

Bias

N

o se

rious

0

Fact

ors

Incr

easin

g Co

nfid

ence

Larg

e ef

fect

N

ot a

pplic

able

0

Dose

-res

pons

e N

ot a

pplic

able

0

Anta

goni

stic

bia

s and

co

nfou

ndin

g N

ot a

pplic

able

0

Fina

l num

eric

al ra

ting

of q

ualit

y of

evi

denc

e 4

Sum

mar

y of

Fin

ding

s

Stat

emen

t on

qual

ity o

f evi

denc

e

Evid

ence

supp

orts

a

high

leve

l of c

onfid

ence

th

at th

e tr

ue e

ffect

lies

cl

ose

to th

at o

f the

he

alth

out

com

e.

Conc

lusio

n

High

leve

l of s

cien

tific

ev

iden

ce th

at th

e cu

rren

tly li

cens

ed o

ral

chol

era

vacc

ines

are

ef

ficac

ious

and

ef

fect

ive

agai

nst

chol

era.

R

efe

ren

ces:

1.

Clem

ens J

D et

al.

Fiel

d tr

ial o

f ora

l cho

lera

vac

cine

s in

Bang

lade

sh: r

esul

ts fr

om th

ree-

year

follo

w-

up e

t al.

Lanc

et 1

990;

335

(868

4): 2

70-2

73.

2.

Sanc

hez J

L et

al.

Prot

ectiv

e ef

ficac

y of

ora

l who

le-c

ell/r

ecom

bina

nt-B

-sub

unit

chol

era

vacc

ine

in

Peru

vian

mili

tary

recr

uits

. Lan

cet 1

994;

344

(893

2): 1

273-

1276

.

Page 12: Evidence to Recommendations Table · The recommendation applies to specific contexts, in specific (sub) populations and in conjunction with other prevention and control measures

Page

12

of 2

9

3.

Tayl

or D

N e

t al.

Two-

year

stud

y of

the

prot

ectiv

e ef

ficac

y of

the

oral

who

le c

ell p

lus r

ecom

bina

nt B

su

buni

t cho

lera

vac

cine

in P

eru.

JID

2000

; 181

(5):

1667

-167

3.

4.

Trac

h DD

et a

l. Fi

eld

tria

l of a

loca

lly p

rodu

ced,

kill

ed, o

ral c

hole

ra v

acci

ne in

Vie

tnam

. Lan

cet 1

997;

34

9(90

47):

231-

235.

5.

Su

r D e

t al.

Effic

acy

and

safe

ty o

f a m

odifi

ed k

illed

-who

le-c

ell o

ral c

hole

ra v

acci

ne in

Indi

a: a

n in

terim

ana

lysis

of a

clu

ster

-ran

dom

ised,

dou

ble-

blin

d, p

lace

bo-c

ontr

olle

d tr

ial.

Lanc

et 2

009;

374

: 16

94-1

702.

6.

Bh

atta

char

ya S

K, e

t al.

5 ye

ar e

ffica

cy o

f a b

ival

ent k

illed

who

le-c

ell o

ral c

hole

ra v

acci

ne in

Kol

kata

, In

dia:

a c

lust

er-r

ando

mise

d, d

oubl

e-bl

ind,

pla

cebo

-con

trol

led

tria

l. La

ncet

201

3; 1

3(12

); 10

50-1

056.

7.

De

sai S

N e

t al.

A Ra

ndom

ized,

Pla

cebo

-Con

trol

led

Tria

l Eva

luat

ing

Safe

ty a

nd Im

mun

ogen

icity

of

the

Kille

d, B

ival

ent,

Who

le-C

ell O

ral C

hole

ra V

acci

ne in

Eth

iopi

a. A

m J

Trop

Med

Hyg

201

5; 9

3(3)

: 52

7-53

3.

8.

Qad

ri, F

et a

l. Ef

ficac

y of

a S

ingl

e-Do

se, I

nact

ivat

ed O

ral C

hole

ra V

acci

ne in

Ban

glad

esh.

NEJ

M 2

016;

37

4: 1

723-

1732

.

9.

Baik

YO

et a

l. A

rand

omize

d, n

on-in

ferio

rity

tria

l com

parin

g tw

o bi

vale

nt k

illed

, who

le c

ell,

oral

ch

oler

a va

ccin

es (E

uvic

hol v

s Sha

ncho

l) in

the

Phili

ppin

es. V

acci

ne 2

015;

33(

46):

6360

-636

5.

10. Q

adri

F et

al.

Feas

ibili

ty a

nd e

ffect

iven

ess o

f ora

l cho

lera

vac

cine

in a

n ur

ban

ende

mic

sett

ing

in

Bang

lade

sh: a

clu

ster

rand

omise

d op

en-la

bel t

rial.

Lanc

et 2

015;

386

:136

2-13

71.

11. v

an L

oon

FPL

et a

l. Fi

eld

tria

l of i

nact

ivat

ed o

ral c

hole

ra v

acci

nes i

n Ba

ngla

desh

: res

ults

from

5 y

ears

of

follo

w-u

p. V

acci

ne 1

996;

14(

2): 1

62-1

66.

12. L

ucas

MES

et a

l. Ef

fect

iven

ess o

f Mas

s Ora

l Cho

lera

Vac

cina

tion

in B

eira

, Moz

ambi

que.

NEJ

M 2

005;

35

2: 7

57-7

67.

13

. Kha

tib A

M e

t al.

Effe

ctiv

enes

s of a

n or

al c

hole

ra v

acci

ne in

Zan

zibar

: fin

ding

s fro

m a

mas

s va

ccin

atio

n ca

mpa

ign

and

obse

rvat

iona

l coh

ort s

tudy

. Lan

cet I

nf D

is 20

12; 1

2(11

): 83

7-84

4.

14. W

ierz

ba T

F et

al.

Effe

ctiv

enes

s of a

n or

al c

hole

ra v

acci

ne c

ampa

ign

to p

reve

nt c

linic

ally

-sig

nific

ant

chol

era

in O

dish

a St

ate,

Indi

a. V

acci

ne 2

015;

33(

21):

2463

-246

9.

15. Iv

ers L

C et

al.

Effe

ctiv

enes

s of r

eact

ive

oral

cho

lera

vac

cina

tion

in ru

ral H

aiti:

a c

ase-

cont

rol s

tudy

an

d bi

as-in

dica

tor a

naly

sis. L

ance

t Glo

bal H

ealth

201

5; 3

(3):

162-

168.

16

. Sev

ere

K et

al.

Effe

ctiv

enes

s of O

ral C

hole

ra V

acci

ne in

Hai

ti: 3

7-M

onth

Fol

low

-Up.

Am

J Tr

op M

ed

Hyg

2016

; 94(

5): 1

136-

1942

. 17

. Luq

uero

FJ e

t al.

Use

of V

ibrio

cho

lera

e va

ccin

e in

an

outb

reak

in G

uine

a. N

ew E

ngla

nd Jo

urna

l of

Med

icin

e 20

14; 3

70(2

2): 2

111-

20.

18. T

hiem

VD

et a

l. Lo

ng-t

erm

effe

ctiv

enes

s aga

inst

cho

lera

of o

ral k

illed

who

le-c

ell v

acci

ne p

rodu

ced

in V

ietn

am. V

acci

ne 2

006;

24(

20):

4297

-430

3.

Page 13: Evidence to Recommendations Table · The recommendation applies to specific contexts, in specific (sub) populations and in conjunction with other prevention and control measures

Page

13

of 2

9

Effi

cacy

an

d E

ffec

tive

nes

s, s

ever

e ch

ole

ra

Po

pu

lati

on

: Non

-pre

gnan

t adu

lts a

nd c

hild

ren

≥ 1

year

old

(Sha

ncho

l/Euv

icho

l/mO

RCVa

x) o

r ≥ 2

yea

rs o

ld

(Duk

oral

) In

terv

enti

on

: 2 d

oses

of t

he c

urre

ntly

ava

ilabl

e ki

lled,

who

le-c

ell o

ral c

hole

ra v

acci

nes (

OCV

s)

Co

mp

aris

on

: Pla

cebo

or n

o va

ccin

e/ot

her p

reve

ntio

n an

d co

ntro

l mea

sure

s (e.

g. W

ASH)

O

utc

om

e: C

ases

of s

ever

e ch

oler

a

Wha

t is t

he e

vide

nce

for p

rote

ctiv

e ef

ficac

y an

d ef

fect

iven

ess a

gain

st se

vere

cho

lera

of t

he c

urre

ntly

av

aila

ble

kille

d, w

hole

cell

OCV

s am

ong

indi

vidu

als ≥

1 y

ear o

ld?

Ra

ting

Adju

stm

ent t

o Ra

ting

Qua

lity

of

Evid

ence

No.

of s

tudi

es/s

tart

ing

ratin

g 5

RCT/

1 ob

serv

atio

nal

4

Fact

ors

decr

easin

g co

nfid

ence

Lim

itatio

n in

stud

y de

sign

No

serio

us

0 In

cons

isten

cy

No

serio

us

0 In

dire

ctne

ss

No

serio

us

0 Im

prec

ision

N

o se

rious

0

Publ

icat

ion

Bias

N

o se

rious

0

Fact

ors

Incr

easin

g Co

nfid

ence

Larg

e ef

fect

N

ot a

pplic

able

0

Dose

-res

pons

e N

ot a

pplic

able

0

Anta

goni

stic

bia

s and

co

nfou

ndin

g N

ot a

pplic

able

0

Fina

l num

eric

al ra

ting

of q

ualit

y of

evi

denc

e 4

Sum

mar

y of

Fin

ding

s

Stat

emen

t on

qual

ity o

f evi

denc

e

Evid

ence

supp

orts

a

high

leve

l of c

onfid

ence

th

at th

e tr

ue e

ffect

lies

cl

ose

to th

e ef

fect

on

the

heal

th o

utco

me.

Conc

lusio

n

High

leve

l of s

cien

tific

ev

iden

ce th

at th

e cu

rren

tly li

cens

ed o

ral

chol

era

vacc

ines

are

ef

ficac

ious

and

ef

fect

ive

in p

rote

ctin

g ag

ains

t sev

ere

chol

era.

R

efe

ren

ces:

1.

Clem

ens J

D et

al.

Fiel

d tr

ial o

f ora

l cho

lera

vac

cine

s in

Bang

lade

sh: r

esul

ts fr

om th

ree-

year

follo

w-

up. L

ance

t 199

0; 3

35(8

684)

: 270

-273

. 2.

Ta

ylor

DN

et a

l. Tw

o-ye

ar st

udy

of th

e pr

otec

tive

effic

acy

of th

e or

al w

hole

cel

l plu

s rec

ombi

nant

B

subu

nit c

hole

ra v

acci

ne in

Per

u. JI

D 20

00; 1

81(5

): 16

67-1

673.

Page 14: Evidence to Recommendations Table · The recommendation applies to specific contexts, in specific (sub) populations and in conjunction with other prevention and control measures

Page

14

of 2

9

3.

Trac

h DD

et a

l. Fi

eld

tria

l of a

loca

lly p

rodu

ced,

kill

ed, o

ral c

hole

ra v

acci

ne in

Vie

tnam

. Lan

cet

1997

; 349

(904

7): 2

31-2

35.

4.

Qad

ri F

et a

l. Ef

ficac

y of

a S

ingl

e-Do

se, I

nact

ivat

ed O

ral C

hole

ra V

acci

ne in

Ban

glad

esh.

NEJ

M

2016

; 374

: 172

3-17

32.

5.

Q

adri

F et

al.

Feas

ibili

ty a

nd e

ffect

iven

ess o

f ora

l cho

lera

vac

cine

in a

n ur

ban

ende

mic

sett

ing

in

Bang

lade

sh: a

clu

ster

rand

omise

d op

en-la

bel t

rial.

Lanc

et 2

015;

386

:136

2-13

71.

6.

Luca

s MES

et a

l. Ef

fect

iven

ess o

f Mas

s Ora

l Cho

lera

Vac

cina

tion

in B

eira

, Moz

ambi

que.

NEJ

M

2005

; 352

: 757

-767

.

Page 15: Evidence to Recommendations Table · The recommendation applies to specific contexts, in specific (sub) populations and in conjunction with other prevention and control measures

Page

15

of 2

9

Effi

cacy

an

d E

ffec

tive

nes

s, <

5 ye

ars

old

, an

y ch

ole

ra

Po

pu

lati

on

: Chi

ldre

n <5

yea

rs o

f age

In

terv

enti

on

: 2 d

oses

of t

he c

urre

ntly

ava

ilabl

e ki

lled,

who

le-c

ell o

ral c

hole

ra v

acci

nes (

OCV

s)

Co

mp

aris

on

: Pla

cebo

or n

o va

ccin

e/ o

ther

pre

vent

ion

and

cont

rol m

easu

res (

e.g.

WAS

H)

Ou

tco

me:

Cas

es o

f cho

lera

(any

seve

rity)

W

hat i

s the

evi

denc

e fo

r pro

tect

ive

effic

acy

and

effe

ctiv

enes

s aga

inst

cho

lera

(any

seve

rity)

of t

he

curr

ently

ava

ilabl

e ki

lled,

who

le c

ell O

CVs a

mon

g in

divi

dual

s <5

year

s of a

ge?

Ra

ting

Adju

stm

ent t

o Ra

ting

Qua

lity

of

Evid

ence

No.

of s

tudi

es/s

tart

ing

ratin

g 9

RCT/

2 ob

serv

atio

nal

4

Fact

ors

decr

easin

g co

nfid

ence

Lim

itatio

n in

stud

y de

sign

No

serio

us

0 In

cons

isten

cy

No

serio

us

0 In

dire

ctne

ss

No

serio

us

0 Im

prec

ision

1 Se

rious

-1

Pu

blic

atio

n Bi

as

No

serio

us

0

Fact

ors

Incr

easin

g Co

nfid

ence

Larg

e ef

fect

N

ot a

pplic

able

0

Dose

-res

pons

e N

ot a

pplic

able

0

Anta

goni

stic

bia

s and

co

nfou

ndin

g N

ot a

pplic

able

0

Fina

l num

eric

al ra

ting

of q

ualit

y of

evi

denc

e 3

Sum

mar

y of

Fin

ding

s

Stat

emen

t on

qual

ity o

f evi

denc

e

Evid

ence

supp

orts

a

mod

erat

e le

vel o

f co

nfid

ence

that

the

true

ef

fect

lies

clo

se to

the

effe

ct o

f tha

t of t

he

estim

ate

of th

e ef

fect

on

the

heal

th o

utco

me.

Conc

lusio

n

Mod

erat

e le

vel o

f sc

ient

ific

evid

ence

that

the

curr

ently

lice

nsed

ora

l ch

oler

a va

ccin

es a

re

effic

acio

us a

nd e

ffect

ive

agai

nst c

hole

ra (a

ny

seve

rity)

. 1 M

ost o

f the

clin

ical

tria

ls w

ere

not p

ower

ed to

car

ryou

t sub

-gro

up a

naly

sis re

sulti

ng in

impr

ecise

poi

nt e

stim

ates

in

chi

ldre

n un

der-

five.

Page 16: Evidence to Recommendations Table · The recommendation applies to specific contexts, in specific (sub) populations and in conjunction with other prevention and control measures

Page

16

of 2

9

Re

fere

nce

s:

1.

Cl

emen

s JD

et a

l. Fi

eld

tria

l of o

ral c

hole

ra v

acci

nes i

n Ba

ngla

desh

: res

ults

from

thre

e-ye

ar fo

llow

-up

et a

l. La

ncet

199

0; 3

35(8

684)

: 270

-273

. 2.

Ta

ylor

DN

et a

l. Tw

o-ye

ar st

udy

of th

e pr

otec

tive

effic

acy

of th

e or

al w

hole

cel

l plu

s rec

ombi

nant

B

subu

nit c

hole

ra v

acci

ne in

Per

u. JI

D 20

00; 1

81(5

): 16

67-1

673.

3.

Tr

ach

DD e

t al.

Fiel

d tr

ial o

f a lo

cally

pro

duce

d, k

illed

, ora

l cho

lera

vac

cine

in V

ietn

am. L

ance

t 199

7;

349(

9047

): 23

1-23

5.

4.

Sur D

et a

l. Ef

ficac

y an

d sa

fety

of a

mod

ified

kill

ed-w

hole

-cel

l ora

l cho

lera

vac

cine

in In

dia:

an

inte

rim a

naly

sis o

f a c

lust

er-r

ando

mise

d, d

oubl

e-bl

ind,

pla

cebo

-con

trol

led

tria

l. La

ncet

200

9; 3

74:

1694

-170

2.

5.

Bhat

tach

arya

SK

et a

l. 5

year

effi

cacy

of a

biv

alen

t kill

ed w

hole

-cel

l ora

l cho

lera

vac

cine

in K

olka

ta,

Indi

a: a

clu

ster

-ran

dom

ised,

dou

ble-

blin

d, p

lace

bo-c

ontr

olle

d tr

ial.

Lanc

et 2

013;

13(

12);

1050

-105

6.

6.

Saha

A e

t al.

Safe

ty a

nd im

mun

ogen

icity

stud

y of

a k

illed

biv

alen

t (O

1 an

d O

139)

who

le-c

ell o

ral

chol

era

vacc

ine

Shan

chol

, in

Bang

lade

shi a

dults

and

chi

ldre

n as

you

ng a

s 1 y

ear o

f age

. Vac

cine

20

11; 2

9(46

): 82

85-8

295.

7.

De

sai S

N e

t al.

A Ra

ndom

ized,

Pla

cebo

-Con

trol

led

Tria

l Eva

luat

ing

Safe

ty a

nd Im

mun

ogen

icity

of t

he

Kille

d, B

ival

ent,

Who

le-C

ell O

ral C

hole

ra V

acci

ne in

Eth

iopi

a. A

m J

Trop

Med

Hyg

201

5; 9

3(3)

: 527

-53

3.

8.

Qad

ri, F

et a

l. Ef

ficac

y of

a S

ingl

e-Do

se, I

nact

ivat

ed O

ral C

hole

ra V

acci

ne in

Ban

glad

esh.

NEJ

M 2

016;

37

4: 1

723-

1732

.

9.

Bhat

tach

arya

SK

et a

l. 5

year

effi

cacy

of a

biv

alen

t kill

ed w

hole

-cel

l ora

l cho

lera

vac

cine

in K

olka

ta,

Indi

a: a

clu

ster

-ran

dom

ised,

dou

ble-

blin

d, p

lace

bo-c

ontr

olle

d tr

ial.

Lanc

et 2

013;

13(

12);

1050

-105

6.

10. L

ucas

MES

et a

l. Ef

fect

iven

ess o

f Mas

s Ora

l Cho

lera

Vac

cina

tion

in B

eira

, Moz

ambi

que.

NEJ

M 2

005;

35

2: 7

57-7

67.

11

. Iver

s LC

et a

l. Ef

fect

iven

ess o

f rea

ctiv

e or

al c

hole

ra v

acci

natio

n in

rura

l Hai

ti: a

cas

e-co

ntro

l stu

dy

and

bias

-indi

cato

r ana

lysis

. Lan

cet G

loba

l Hea

lth 2

015;

3(3

): 16

2-16

8.

Page 17: Evidence to Recommendations Table · The recommendation applies to specific contexts, in specific (sub) populations and in conjunction with other prevention and control measures

Page

17

of 2

9

Effi

cacy

an

d E

ffec

tive

nes

s, <

5 ye

ars

old

, sev

ere

cho

lera

P

op

ula

tio

n: C

hild

ren

<5 y

ears

of a

ge

Inte

rven

tio

n: 2

dos

es o

f the

cur

rent

ly a

vaila

ble

kille

d, w

hole

-cel

l ora

l cho

lera

vac

cine

s (O

CVs)

C

om

par

iso

n: P

lace

bo o

r no

vacc

ine/

othe

r pre

vent

ion

and

cont

rol m

easu

res (

e.g.

WAS

H)

Ou

tco

me:

Cas

es o

f sev

ere

chol

era

W

hat i

s the

evi

denc

e fo

r pro

tect

ive

effic

acy

and

effe

ctiv

enes

s aga

inst

seve

re c

hole

ra o

f the

cur

rent

ly

avai

labl

e ki

lled,

who

le ce

ll O

CVs a

mon

g in

divi

dual

s <5

yea

rs o

f age

?

Ratin

g Ad

just

men

t to

Ratin

g

Qua

lity

of

Evid

ence

No.

of s

tudi

es/s

tart

ing

ratin

g 2

RCT

4

Fact

ors

decr

easin

g co

nfid

ence

Lim

itatio

n in

stud

y de

sign

No

serio

us

0 In

cons

isten

cy

No

serio

us

0 In

dire

ctne

ss

No

serio

us

0 Im

prec

ision

1 N

o se

rious

-1

Pu

blic

atio

n Bi

as

No

serio

us

0

Fact

ors

Incr

easin

g Co

nfid

ence

Larg

e ef

fect

N

ot a

pplic

able

0

Dose

-res

pons

e N

ot a

pplic

able

0

Anta

goni

stic

bia

s and

co

nfou

ndin

g N

ot a

pplic

able

0

Fina

l num

eric

al ra

ting

of q

ualit

y of

evi

denc

e 3

Sum

mar

y of

Fin

ding

s

Stat

emen

t on

qual

ity o

f evi

denc

e

Evid

ence

supp

orts

a

mod

erat

e le

vel o

f co

nfid

ence

that

the

true

ef

fect

lies

clo

se to

that

of

the

estim

ate

of th

e ef

fect

on

the

heal

th o

utco

me.

Conc

lusio

n

Mod

erat

e le

vel o

f sci

entif

ic

evid

ence

that

the

curr

ently

lic

ense

d or

al c

hole

ra

vacc

ines

are

effi

caci

ous

and

effe

ctiv

e ag

ains

t se

vere

cho

lera

in c

hild

ren

unde

r 5.

1 Mos

t of t

he c

linic

al tr

ials

wer

e no

t pow

ered

to c

arry

out s

ub-g

roup

ana

lysis

resu

lting

in im

prec

ise p

oint

est

imat

es in

ch

ildre

n un

der-

five.

Re

fere

nce

s:

1.

Qad

ri F

et a

l. Ef

ficac

y of

a S

ingl

e-Do

se, I

nact

ivat

ed O

ral C

hole

ra V

acci

ne in

Ban

glad

esh.

NEJ

M 2

016;

37

4: 1

723-

1732

.

2.

Qad

ri F

et a

l. Fe

asib

ility

and

effe

ctiv

enes

s of o

ral c

hole

ra v

acci

ne in

an

urba

n en

dem

ic se

ttin

g in

Ba

ngla

desh

: a c

lust

er ra

ndom

ised

open

-labe

l tria

l. La

ncet

201

5; 3

86:1

362-

1371

.

Page 18: Evidence to Recommendations Table · The recommendation applies to specific contexts, in specific (sub) populations and in conjunction with other prevention and control measures

Page

18

of 2

9

Effi

cacy

an

d E

ffec

tive

nes

s, 5

-14

year

s o

ld, a

ny

cho

lera

P

op

ula

tio

n: C

hild

ren

and

adol

esce

nts 5

-14

year

s of a

ge

Inte

rven

tio

n: 2

dos

es o

f the

cur

rent

ly a

vaila

ble

kille

d, w

hole

-cel

l ora

l cho

lera

vac

cine

s (O

CVs)

C

om

par

iso

n: P

lace

bo o

r no

vacc

ine/

othe

r pre

vent

ion

and

cont

rol m

easu

res (

e.g.

WAS

H)

Ou

tco

me:

Cas

es o

f cho

lera

(any

seve

rity)

W

hat i

s the

evi

denc

e fo

r pro

tect

ive

effic

acy

and

effe

ctiv

enes

s aga

inst

cho

lera

(any

seve

rity)

of t

he

curr

ently

ava

ilabl

e ki

lled,

who

le c

ell O

CVs a

mon

g in

divi

dual

s 5-1

4 ye

ars o

f age

old

?

Ratin

g Ad

just

men

t to

Ratin

g

Qua

lity

of

Evid

ence

No.

of s

tudi

es/s

tart

ing

ratin

g 7

RCT

4

Fact

ors

decr

easin

g co

nfid

ence

Lim

itatio

n in

stud

y de

sign

No

serio

us

0 In

cons

isten

cy

No

serio

us

0 In

dire

ctne

ss

No

serio

us

0 Im

prec

ision

N

o se

rious

0

Publ

icat

ion

Bias

N

o se

rious

0

Fact

ors

Incr

easin

g Co

nfid

ence

Larg

e ef

fect

N

ot a

pplic

able

0

Dose

-res

pons

e N

ot a

pplic

able

0

Anta

goni

stic

bia

s and

co

nfou

ndin

g N

ot a

pplic

able

0

Fina

l num

eric

al ra

ting

of q

ualit

y of

evi

denc

e 4

Sum

mar

y of

Fin

ding

s

Stat

emen

t on

qual

ity o

f evi

denc

e

Evid

ence

supp

orts

a

high

leve

l of c

onfid

ence

th

at th

e tr

ue e

ffect

lies

cl

ose

to th

at o

f the

es

timat

e on

the

effe

ct

of th

e he

alth

out

com

e.

Conc

lusio

n

High

leve

l of s

cien

tific

ev

iden

ce th

at th

e cu

rren

tly li

cens

ed o

ral

chol

era

vacc

ines

are

ef

ficac

ious

and

effe

ctiv

e ag

ains

t cho

lera

of a

ny

seve

rity

in in

divi

dual

s 5-

14 y

ears

of a

ge.

Page 19: Evidence to Recommendations Table · The recommendation applies to specific contexts, in specific (sub) populations and in conjunction with other prevention and control measures

Page

19

of 2

9

Re

fere

nce

s:

1.

Ta

ylor

DN

et a

l. Tw

o-ye

ar st

udy

of th

e pr

otec

tive

effic

acy

of th

e or

al w

hole

cel

l plu

s rec

ombi

nant

B

subu

nit c

hole

ra v

acci

ne in

Per

u. JI

D 20

00; 1

81(5

): 16

67-1

673.

2.

Su

r D e

t al.

Effic

acy

and

safe

ty o

f a m

odifi

ed k

illed

-who

le-c

ell o

ral c

hole

ra v

acci

ne in

Indi

a: a

n in

terim

an

alys

is of

a c

lust

er-r

ando

mise

d, d

oubl

e-bl

ind,

pla

cebo

-con

trol

led

tria

l. La

ncet

200

9; 3

74: 1

694-

1702

. 3.

Bh

atta

char

ya S

K et

al.

5 ye

ar e

ffica

cy o

f a b

ival

ent k

illed

who

le-c

ell o

ral c

hole

ra v

acci

ne in

Kol

kata

, In

dia:

a c

lust

er-r

ando

mise

d, d

oubl

e-bl

ind,

pla

cebo

-con

trol

led

tria

l. La

ncet

201

3; 1

3(12

); 10

50-1

056.

4.

Sa

ha A

et a

l. Sa

fety

and

imm

unog

enic

ity st

udy

of a

kill

ed b

ival

ent (

O1

and

O13

9) w

hole

-cel

l ora

l ch

oler

a va

ccin

e Sh

anch

ol, i

n Ba

ngla

desh

i adu

lts a

nd c

hild

ren

as y

oung

as 1

yea

r of a

ge. V

acci

ne 2

011;

29

(46)

: 828

5-82

95.

5.

Desa

i SN

et a

l. A

Rand

omize

d, P

lace

bo-C

ontr

olle

d Tr

ial E

valu

atin

g Sa

fety

and

Imm

unog

enic

ity o

f the

Ki

lled,

Biv

alen

t, W

hole

-Cel

l Ora

l Cho

lera

Vac

cine

in E

thio

pia.

Am

J Tr

op M

ed H

yg 2

015;

93(

3): 5

27-

533.

6.

Q

adri

F et

al.

Effic

acy

of a

Sin

gle-

Dose

, Ina

ctiv

ated

Ora

l Cho

lera

Vac

cine

in B

angl

ades

h. N

EJM

201

6;

374:

172

3-17

32.

7.

Bh

atta

char

ya S

K et

al.

5 ye

ar e

ffica

cy o

f a b

ival

ent k

illed

who

le-c

ell o

ral c

hole

ra v

acci

ne in

Kol

kata

, In

dia:

a c

lust

er-r

ando

mise

d, d

oubl

e-bl

ind,

pla

cebo

-con

trol

led

tria

l. La

ncet

201

3; 1

3(12

); 10

50-1

056.

Page 20: Evidence to Recommendations Table · The recommendation applies to specific contexts, in specific (sub) populations and in conjunction with other prevention and control measures

Page

20

of 2

9

Effi

cacy

an

d E

ffec

tive

nes

s, 5

-14

year

s o

ld, s

ever

e ch

ole

ra

Po

pu

lati

on

: Chi

ldre

n an

d ad

oles

cent

s 5-1

4 ye

ars o

f age

In

terv

enti

on

: 2 d

oses

of t

he c

urre

ntly

ava

ilabl

e ki

lled,

who

le-c

ell o

ral c

hole

ra v

acci

nes (

OCV

s)

Co

mp

aris

on

: Pla

cebo

or n

o va

ccin

e/ot

her p

reve

ntio

n an

d co

ntro

l mea

sure

s (e.

g. W

ASH)

O

utc

om

e: C

ases

of s

ever

e ch

oler

a

Wha

t is t

he e

vide

nce

for p

rote

ctiv

e ef

ficac

y an

d ef

fect

iven

ess a

gain

st se

vere

cho

lera

of t

he c

urre

ntly

av

aila

ble

kille

d, w

hole

cell

OCV

s am

ong

indi

vidu

als 5

-14

year

s of a

ge?

Ra

ting

Adju

stm

ent t

o Ra

ting

Qua

lity

of

Evid

ence

No.

of s

tudi

es/s

tart

ing

ratin

g 2

RCT

4

Fact

ors

decr

easin

g co

nfid

ence

Lim

itatio

n in

stud

y de

sign

No

serio

us

0 In

cons

isten

cy

No

serio

us

0 In

dire

ctne

ss

No

serio

us

0 Im

prec

ision

N

o se

rious

0

Publ

icat

ion

Bias

N

o se

rious

0

Fact

ors

Incr

easin

g Co

nfid

ence

Larg

e ef

fect

N

ot a

pplic

able

0

Dose

-res

pons

e N

ot a

pplic

able

0

Anta

goni

stic

bia

s and

co

nfou

ndin

g N

ot a

pplic

able

0

Fina

l num

eric

al ra

ting

of q

ualit

y of

evi

denc

e 4

Sum

mar

y of

Fin

ding

s

Stat

emen

t on

qual

ity o

f evi

denc

e

Evid

ence

supp

orts

a

high

leve

l of c

onfid

ence

th

at th

e tr

ue e

ffect

lies

cl

ose

to th

e es

timat

e of

th

e ef

fect

on

the

heal

th

outc

ome.

Conc

lusio

n

High

leve

l of s

cien

tific

ev

iden

ce th

at th

e cu

rren

tly li

cens

ed o

ral

chol

era

vacc

ines

are

ef

ficac

ious

and

effe

ctiv

e in

chi

ldre

n an

d ad

oles

cent

s 5-1

4 ye

ars

agai

nst s

ever

e ch

oler

a.

Re

fere

nce

s:

1.

Q

adri

F et

al.

Effic

acy

of a

Sin

gle-

Dose

, Ina

ctiv

ated

Ora

l Cho

lera

Vac

cine

in B

angl

ades

h. N

EJM

201

6;

374:

172

3-17

32.

2.

Q

adri

F et

al.

Feas

ibili

ty a

nd e

ffect

iven

ess o

f ora

l cho

lera

vac

cine

in a

n ur

ban

ende

mic

sett

ing

in

Bang

lade

sh: a

clu

ster

rand

omise

d op

en-la

bel t

rial.

Lanc

et 2

015;

386

:136

2-13

71.

Page 21: Evidence to Recommendations Table · The recommendation applies to specific contexts, in specific (sub) populations and in conjunction with other prevention and control measures

Page

21

of 2

9

Effi

cacy

an

d E

ffec

tive

nes

s, >

14 y

ears

old

, an

y ch

ole

ra

Po

pu

lati

on

: Ado

lesc

ents

and

adu

lts >

14 y

ears

of a

ge

Inte

rven

tio

n: 2

dos

es o

f the

cur

rent

ly a

vaila

ble

kille

d, w

hole

-cel

l ora

l cho

lera

vac

cine

s (O

CVs)

C

om

par

iso

n: P

lace

bo o

r no

vacc

ine/

othe

r pre

vent

ion

and

cont

rol m

easu

res (

e.g.

WAS

H)

Ou

tco

me:

Cas

es o

f cho

lera

W

hat i

s the

evi

denc

e fo

r pro

tect

ive

effic

acy

and

effe

ctiv

enes

s aga

inst

cho

lera

(any

seve

rity)

of t

he

curr

ently

ava

ilabl

e ki

lled,

who

le c

ell O

CVs a

mon

g in

divi

dual

s ≥ 1

4 ye

ars o

f age

?

Ratin

g Ad

just

men

t to

Ratin

g

Qua

lity

of

Evid

ence

No.

of s

tudi

es/s

tart

ing

ratin

g 9

RCT/

2 O

bser

vatio

nal

4

Fact

ors

decr

easin

g co

nfid

ence

Lim

itatio

n in

stud

y de

sign

No

serio

us

0 In

cons

isten

cy

No

serio

us

0 In

dire

ctne

ss

No

serio

us

0 Im

prec

ision

N

o se

rious

0

Publ

icat

ion

Bias

N

o se

rious

0

Fact

ors

Incr

easin

g Co

nfid

ence

Larg

e ef

fect

N

ot a

pplic

able

0

Dose

-res

pons

e N

ot a

pplic

able

0

Anta

goni

stic

bia

s and

co

nfou

ndin

g N

ot a

pplic

able

0

Fina

l num

eric

al ra

ting

of q

ualit

y of

evi

denc

e 4

Sum

mar

y of

Fin

ding

s

Stat

emen

t on

qual

ity o

f evi

denc

e

Evid

ence

supp

orts

a

high

leve

l of c

onfid

ence

th

at th

e tr

ue e

ffect

lies

cl

ose

to th

e es

timat

e of

th

e ef

fect

on

the

heal

th

outc

ome.

Conc

lusio

n

High

leve

l of s

cien

tific

ev

iden

ce th

at th

e cu

rren

tly li

cens

ed o

ral

chol

era

vacc

ines

are

ef

ficac

ious

and

ef

fect

ive

in in

divi

dual

s >1

4 ye

ars o

f age

ag

ains

t cho

lera

.

Page 22: Evidence to Recommendations Table · The recommendation applies to specific contexts, in specific (sub) populations and in conjunction with other prevention and control measures

Page

22

of 2

9

Re

fere

nce

s:

1.

Cl

emen

s JD

et a

l. Fi

eld

tria

l of o

ral c

hole

ra v

acci

nes i

n Ba

ngla

desh

: res

ults

from

thre

e-ye

ar fo

llow

-up

et a

l. La

ncet

199

0; 3

35(8

684)

: 270

-273

. 2.

Ta

ylor

DN

et a

l. Tw

o-ye

ar st

udy

of th

e pr

otec

tive

effic

acy

of th

e or

al w

hole

cel

l plu

s rec

ombi

nant

B

subu

nit c

hole

ra v

acci

ne in

Per

u. JI

D 20

00; 1

81(5

): 16

67-1

673.

3.

Tr

ach

DD e

t al.

Fiel

d tr

ial o

f a lo

cally

pro

duce

d, k

illed

, ora

l cho

lera

vac

cine

in V

ietn

am. L

ance

t 199

7;

349(

9047

): 23

1-23

5.

4.

Sur D

et a

l. Ef

ficac

y an

d sa

fety

of a

mod

ified

kill

ed-w

hole

-cel

l ora

l cho

lera

vac

cine

in In

dia:

an

inte

rim a

naly

sis o

f a c

lust

er-r

ando

mise

d, d

oubl

e-bl

ind,

pla

cebo

-con

trol

led

tria

l. La

ncet

200

9; 3

74:

1694

-170

2.

5.

Bhat

tach

arya

SK

et a

l. 5

year

effi

cacy

of a

biv

alen

t kill

ed w

hole

-cel

l ora

l cho

lera

vac

cine

in K

olka

ta,

Indi

a: a

clu

ster

-ran

dom

ised,

dou

ble-

blin

d, p

lace

bo-c

ontr

olle

d tr

ial.

Lanc

et 2

013;

13(

12);

1050

-105

6.

6.

Saha

A e

t al.

Safe

ty a

nd im

mun

ogen

icity

stud

y of

a k

illed

biv

alen

t (O

1 an

d O

139)

who

le-c

ell o

ral

chol

era

vacc

ine

Shan

chol

, in

Bang

lade

shi a

dults

and

chi

ldre

n as

you

ng a

s 1 y

ear o

f age

. Vac

cine

20

11; 2

9(46

): 82

85-8

295.

7.

De

sai S

N e

t al.

A Ra

ndom

ized,

Pla

cebo

-Con

trol

led

Tria

l Eva

luat

ing

Safe

ty a

nd Im

mun

ogen

icity

of t

he

Kille

d, B

ival

ent,

Who

le-C

ell O

ral C

hole

ra V

acci

ne in

Eth

iopi

a. A

m J

Trop

Med

Hyg

201

5; 9

3(3)

: 527

-53

3.

8.

Qad

ri F

et a

l. Ef

ficac

y of

a S

ingl

e-Do

se, I

nact

ivat

ed O

ral C

hole

ra V

acci

ne in

Ban

glad

esh.

NEJ

M 2

016;

37

4: 1

723-

1732

.

9.

van

Loon

FPL

et a

l. Fi

eld

tria

l of i

nact

ivat

ed o

ral c

hole

ra v

acci

nes i

n Ba

ngla

desh

: res

ults

from

5 y

ears

of

follo

w-u

p. V

acci

ne 1

996;

14(

2): 1

62-1

66.

10. L

ucas

MES

et a

l. Ef

fect

iven

ess o

f Mas

s Ora

l Cho

lera

Vac

cina

tion

in B

eira

, Moz

ambi

que.

NEJ

M 2

005;

35

2: 7

57-7

67.

11

. Iver

s LC

et a

l. Ef

fect

iven

ess o

f rea

ctiv

e or

al c

hole

ra v

acci

natio

n in

rura

l Hai

ti: a

cas

e-co

ntro

l stu

dy

and

bias

-indi

cato

r ana

lysis

. Lan

cet G

loba

l Hea

lth 2

015;

3(3

): 16

2-16

8.

Page 23: Evidence to Recommendations Table · The recommendation applies to specific contexts, in specific (sub) populations and in conjunction with other prevention and control measures

Page

23

of 2

9

Effi

cacy

an

d E

ffec

tive

nes

s, >

14 y

ears

old

, sev

ere

cho

lera

P

op

ula

tio

n: A

dole

scen

ts a

nd a

dults

>14

yea

rs o

f age

In

terv

enti

on

: 2 d

oses

of t

he c

urre

ntly

ava

ilabl

e ki

lled,

who

le-c

ell o

ral c

hole

ra v

acci

nes (

OCV

s)

Co

mp

aris

on

: Pla

cebo

or n

o va

ccin

e/ot

her p

reve

ntio

n an

d co

ntro

l mea

sure

s (e.

g. W

ASH)

O

utc

om

e: C

ases

of s

ever

e ch

oler

a

Wha

t is t

he e

vide

nce

for p

rote

ctiv

e ef

ficac

y an

d ef

fect

iven

ess a

gain

st se

vere

cho

lera

of t

he c

urre

ntly

av

aila

ble

kille

d, w

hole

cell

OCV

s am

ong

indi

vidu

als ≥

14

year

s of a

ge?

Ra

ting

Adju

stm

ent t

o Ra

ting

Qua

lity

of

Evid

ence

No.

of s

tudi

es/s

tart

ing

ratin

g 2

RCT

4

Fact

ors

decr

easin

g co

nfid

ence

Lim

itatio

n in

stud

y de

sign

No

serio

us

0 In

cons

isten

cy

No

serio

us

0 In

dire

ctne

ss

No

serio

us

0 Im

prec

ision

N

o se

rious

0

Publ

icat

ion

Bias

N

o se

rious

0

Fact

ors

Incr

easin

g Co

nfid

ence

Larg

e ef

fect

N

ot a

pplic

able

0

Dose

-res

pons

e N

ot a

pplic

able

0

Anta

goni

stic

bia

s and

co

nfou

ndin

g N

ot a

pplic

able

0

Fina

l num

eric

al ra

ting

of q

ualit

y of

evi

denc

e 4

Sum

mar

y of

Fin

ding

s

Stat

emen

t on

qual

ity o

f evi

denc

e

Evid

ence

supp

orts

a

high

leve

l of c

onfid

ence

th

at th

e tr

ue e

ffect

lies

cl

ose

to th

e es

timat

e of

th

e ef

fect

on

the

heal

th

outc

ome.

Conc

lusio

n

High

leve

l of s

cien

tific

ev

iden

ce th

at th

e cu

rren

tly li

cens

ed o

ral

chol

era

vacc

ines

are

ef

ficac

ious

and

effe

ctiv

e ag

ains

t sev

ere

chol

era

in in

divi

dual

s ove

r 14

year

s of a

ge.

Re

fere

nce

s:

1.

Q

adri,

F e

t al.

Effic

acy

of a

Sin

gle-

Dose

, Ina

ctiv

ated

Ora

l Cho

lera

Vac

cine

in B

angl

ades

h. N

EJM

201

6;

374:

172

3-17

32.

2.

Q

adri

F et

al.

Feas

ibili

ty a

nd e

ffect

iven

ess o

f ora

l cho

lera

vac

cine

in a

n ur

ban

ende

mic

sett

ing

in

Bang

lade

sh: a

clu

ster

rand

omise

d op

en-la

bel t

rial.

Lanc

et 2

015;

386

:136

2-13

71.

Page 24: Evidence to Recommendations Table · The recommendation applies to specific contexts, in specific (sub) populations and in conjunction with other prevention and control measures

Page

24

of 2

9

Effi

cacy

an

d E

ffec

tive

nes

s o

f a

sin

gle

do

se

Po

pu

lati

on

: Non

-pre

gnan

t adu

lts a

nd c

hild

ren

≥ 1

year

old

(Sha

ncho

l/Euv

icho

l/mO

RCVa

x) o

r ≥ 2

yea

rs o

ld

(Duk

oral

) In

terv

enti

on

: Sin

gle

dose

of t

he c

urre

ntly

ava

ilabl

e ki

lled,

who

le-c

ell o

ral c

hole

ra v

acci

nes (

OCV

s)

Co

mp

aris

on

: Pla

cebo

or n

o va

ccin

e/ot

her p

reve

ntio

n an

d co

ntro

l mea

sure

s (e.

g. W

ASH)

O

utc

om

e: C

ases

of c

hole

ra

Wha

t is t

he e

vide

nce

for p

rote

ctiv

e ef

ficac

y an

d ef

fect

iven

ess o

f a si

ngle

dos

e o

f the

cur

rent

ly a

vaila

ble

kille

d, w

hole

cel

l OCV

s am

ong

indi

vidu

als ≥

1 y

ear o

ld?

Ra

ting

Adju

stm

ent t

o Ra

ting

Qua

lity

of

Evid

ence

No.

of s

tudi

es/s

tart

ing

ratin

g 1

RCT/

3

Obs

erva

tiona

l 4

Fact

ors

decr

easin

g co

nfid

ence

Lim

itatio

n in

stud

y de

sign

No

serio

us

0 In

cons

isten

cy

No

serio

us

0 In

dire

ctne

ss

No

serio

us

0 Im

prec

ision

N

o se

rious

0

Publ

icat

ion

Bias

N

o se

rious

0

Fact

ors

Incr

easin

g Co

nfid

ence

Larg

e ef

fect

N

ot a

pplic

able

0

Dose

-res

pons

e N

ot a

pplic

able

0

Anta

goni

stic

bia

s and

co

nfou

ndin

g N

ot a

pplic

able

0

Fina

l num

eric

al ra

ting

of q

ualit

y of

evi

denc

e 4

Sum

mar

y of

Fin

ding

s

Stat

emen

t on

qual

ity o

f evi

denc

e

Evid

ence

supp

orts

a

high

leve

l of c

onfid

ence

th

at th

e tr

ue e

ffect

lies

cl

ose

to th

e es

timat

e of

th

e ef

fect

on

the

heal

th

outc

ome.

Conc

lusio

n

High

leve

l of s

cien

tific

ev

iden

ce th

at th

e cu

rren

tly li

cens

ed o

ral

chol

era

vacc

ines

are

ef

ficac

ious

for a

t lea

st 6

m

onth

s usin

g a

singl

e do

se.

Page 25: Evidence to Recommendations Table · The recommendation applies to specific contexts, in specific (sub) populations and in conjunction with other prevention and control measures

Page

25

of 2

9

Re

fere

nce

s:

1.

Q

adri

F et

al.

Effic

acy

of a

Sin

gle-

Dose

, Ina

ctiv

ated

Ora

l Cho

lera

Vac

cine

in B

angl

ades

h. N

EJM

201

6;

374:

172

3-17

32.

2.

Kh

atib

AM

et a

l. Ef

fect

iven

ess o

f an

oral

cho

lera

vac

cine

in Z

anzib

ar: f

indi

ngs f

rom

a m

ass

vacc

inat

ion

cam

paig

n an

d ob

serv

atio

nal c

ohor

t stu

dy. L

ance

t Inf

Dis

2012

; 12(

11):

837-

844.

3.

W

ierz

ba T

F et

al.

Effe

ctiv

enes

s of a

n or

al c

hole

ra v

acci

ne c

ampa

ign

to p

reve

nt c

linic

ally

-sig

nific

ant

chol

era

in O

dish

a St

ate,

Indi

a. V

acci

ne 2

015;

33(

21):

2463

-246

9.

4.

Iver

s LC

et a

l. Ef

fect

iven

ess o

f rea

ctiv

e or

al c

hole

ra v

acci

natio

n in

rura

l Hai

ti: a

cas

e-co

ntro

l stu

dy

and

bias

-indi

cato

r ana

lysis

. Lan

cet G

loba

l Hea

lth 2

015;

3(3

): 16

2-16

8.

5.

Azm

an A

S et

al.

Effe

ctiv

enes

s of o

ne d

ose

of o

ral c

hole

ra v

acci

ne in

resp

onse

to a

n ou

tbre

ak: a

cas

e-co

hort

stud

y. L

ance

t Glo

b He

alth

. 201

6 N

ov;4

(11)

:e85

6-e8

63.

Page 26: Evidence to Recommendations Table · The recommendation applies to specific contexts, in specific (sub) populations and in conjunction with other prevention and control measures

Page

26

of 2

9

Du

rati

on

of

pro

tect

ion

fo

r at

leas

t 3

year

s

Po

pu

lati

on

: Non

-pre

gnan

t adu

lts a

nd c

hild

ren

≥ 1

year

old

(Sha

ncho

l/Euv

icho

l/mO

RCVa

x) o

r ≥ 2

yea

rs o

ld

(Duk

oral

) In

terv

enti

on

: 2 d

oses

of t

he c

urre

ntly

ava

ilabl

e ki

lled,

who

le-c

ell o

ral c

hole

ra v

acci

nes (

OCV

s)

Co

mp

aris

on

: Pla

cebo

or n

o va

ccin

e/ o

ther

pre

vent

ion

and

cont

rol m

easu

res (

e.g.

WAS

H)

Ou

tco

me:

Cas

es o

f cho

lera

W

hat i

s the

evi

denc

e fo

r pro

tect

ive

effic

acy,

eff

ectiv

enes

s, a

nd d

urat

ion

of th

e cu

rren

tly a

vaila

ble

kille

d,

who

le c

ell O

CVs d

urin

g th

e fir

st 3

yea

rs fo

llow

ing

imm

uniz

atio

n am

ong

indi

vidu

als ≥

1 y

ear o

ld?

Ra

ting

Adju

stm

ent t

o Ra

ting

Qua

lity

of

Evid

ence

No.

of s

tudi

es/s

tart

ing

ratin

g 3

RCT/

2

Obs

erva

tiona

l 4

Fact

ors

decr

easin

g co

nfid

ence

Lim

itatio

n in

stud

y de

sign

No

serio

us

0 In

cons

isten

cy

No

serio

us

0 In

dire

ctne

ss

No

serio

us

0 Im

prec

ision

N

o se

rious

0

Publ

icat

ion

Bias

N

o se

rious

0

Fact

ors

Incr

easin

g Co

nfid

ence

Larg

e ef

fect

2 N

ot a

pplic

able

0

Dose

-res

pons

e N

ot a

pplic

able

0

Anta

goni

stic

bia

s and

co

nfou

ndin

g N

ot a

pplic

able

0

Fina

l num

eric

al ra

ting

of q

ualit

y of

evi

denc

e 4

Sum

mar

y of

Fin

ding

s

Stat

emen

t on

qual

ity o

f evi

denc

e

Evid

ence

supp

orts

a

high

leve

l of c

onfid

ence

th

at th

e tr

ue e

ffect

lies

cl

ose

to th

e es

timat

e of

th

e ef

fect

on

the

heal

th

outc

ome

Conc

lusio

n

High

leve

l of e

vide

nce

that

the

curr

ently

av

aila

ble

oral

cho

lera

va

ccin

es w

ith a

2-d

ose

sche

dule

are

effi

caci

ous

and

effe

ctiv

e fo

r at

leas

t 3 y

ears

am

ong

adul

ts, b

ut n

ot a

mon

g yo

ung

child

ren

1 –

5 ye

ars o

ld.

Page 27: Evidence to Recommendations Table · The recommendation applies to specific contexts, in specific (sub) populations and in conjunction with other prevention and control measures

Page

27

of 2

9

Re

fere

nce

s:

1.

Cl

emen

s JD,

Sac

k DA

, Har

ris JR

et a

l. Fi

eld

tria

l of o

ral c

hole

ra v

acci

nes i

n Ba

ngla

desh

: res

ults

from

th

ree-

year

follo

w-u

p et

al.

Lanc

et 1

990;

335

(868

4): 2

70-2

73.

2.

Bhat

tach

arya

SK,

Sur

D, A

li M

et a

l. 5

year

effi

cacy

of a

biv

alen

t kill

ed w

hole

-cel

l ora

l cho

lera

vac

cine

in

Kol

kata

, Ind

ia: a

clu

ster

-ran

dom

ised,

dou

ble-

blin

d, p

lace

bo-c

ontr

olle

d tr

ial.

Lanc

et 2

013;

13(

12);

1050

-105

6.

3. v

an L

oon

FPL,

Cle

men

s JD,

Cha

krab

orty

MR

et a

l. Fi

eld

tria

l of i

nact

ivat

ed o

ral c

hole

ra v

acci

nes i

n Ba

ngla

desh

: res

ults

from

5 y

ears

of f

ollo

w-u

p. V

acci

ne 1

996;

14(

2): 1

62-1

66.

4.

Seve

re K

, Rou

zier V

, Ang

lade

SB

et a

l. Ef

fect

iven

ess o

f Ora

l Cho

lera

Vac

cine

in H

aiti:

37-

Mon

th

Follo

w-U

p. A

m J

Trop

Med

Hyg

201

6; 9

4(5)

: 113

6-19

42.

5.

Thie

m V

D, D

een

JL, v

on S

eidl

ein

L et

al.

Long

-ter

m e

ffect

iven

ess a

gain

st c

hole

ra o

f ora

l kill

ed w

hole

-ce

ll va

ccin

e pr

oduc

ed in

Vie

tnam

. Vac

cine

2006

; 24(

20):

4297

-430

3.

Page 28: Evidence to Recommendations Table · The recommendation applies to specific contexts, in specific (sub) populations and in conjunction with other prevention and control measures

Page

28

of 2

9

Du

rati

on

of

pro

tect

ion

fo

r at

leas

t 5

year

s

Po

pu

lati

on

: Non

-pre

gnan

t adu

lts a

nd c

hild

ren

≥ 1

year

old

(Sha

ncho

l/Euv

icho

l/mO

RCVa

x) o

r ≥ 2

yea

rs o

ld

(Duk

oral

) In

terv

enti

on

: 2 d

oses

of t

he c

urre

ntly

ava

ilabl

e ki

lled,

who

le-c

ell o

ral c

hole

ra v

acci

nes (

OCV

s)

Co

mp

aris

on

: Pla

cebo

or n

o va

ccin

e/ o

ther

pre

vent

ion

and

cont

rol m

easu

res (

e.g.

WAS

H)

Ou

tco

me:

Cas

es o

f cho

lera

W

hat i

s the

evi

denc

e fo

r pro

tect

ive

effic

acy,

eff

ectiv

enes

s, a

nd d

urat

ion

of th

e cu

rren

tly a

vaila

ble

kille

d,

who

le c

ell O

CVs d

urin

g th

e fir

st 5

yea

rs fo

llow

ing

imm

uniz

atio

n am

ong

indi

vidu

als ≥

1 y

ear o

ld?

Ra

ting

Adju

stm

ent t

o Ra

ting

Qua

lity

of

Evid

ence

No.

of s

tudi

es/s

tart

ing

ratin

g 1

RCT/

1

Obs

erva

tiona

l 4

Fact

ors

decr

easin

g co

nfid

ence

Lim

itatio

n in

stud

y de

sign

Serio

us1

-1

Inco

nsist

ency

N

o se

rious

0

Indi

rect

ness

N

o se

rious

0

Impr

ecisi

on

Serio

us2

-1

Publ

icat

ion

Bias

N

o se

rious

0

Fact

ors

Incr

easin

g Co

nfid

ence

Larg

e ef

fect

2 N

ot a

pplic

able

0

Dose

-res

pons

e N

ot a

pplic

able

0

Anta

goni

stic

bia

s and

co

nfou

ndin

g N

ot a

pplic

able

0

Fina

l num

eric

al ra

ting

of q

ualit

y of

evi

denc

e 2

Sum

mar

y of

Fin

ding

s

Stat

emen

t on

qual

ity o

f evi

denc

e

Evid

ence

supp

orts

a

limite

d le

vel o

f co

nfid

ence

that

the

true

effe

ct li

es c

lose

to

the

estim

ate

of th

e ef

fect

on

the

heal

th

outc

ome

Conc

lusio

n

Low

leve

l of e

vide

nce

that

the

curr

ently

av

aila

ble

oral

cho

lera

va

ccin

es w

ith a

2-d

ose

sche

dule

are

effi

caci

ous

and

effe

ctiv

e fo

r at

leas

t 5 y

ears

. 1

High

rate

of l

oss t

o fo

llow

-up.

2Do

wng

rade

d as

ther

e w

ere

smal

l sam

ple

sizes

incl

uded

in th

e st

udie

s to

asse

ss th

e ou

tcom

e of

dur

atio

n of

pro

tect

ion.

Page 29: Evidence to Recommendations Table · The recommendation applies to specific contexts, in specific (sub) populations and in conjunction with other prevention and control measures

Page

29

of 2

9

Re

fere

nce

s:

1.

Bh

atta

char

ya S

K, S

ur D

, Ali

M e

t al.

5 ye

ar e

ffica

cy o

f a b

ival

ent k

illed

who

le-c

ell o

ral c

hole

ra v

acci

ne

in K

olka

ta, I

ndia

: a c

lust

er-r

ando

mise

d, d

oubl

e-bl

ind,

pla

cebo

-con

trol

led

tria

l. La

ncet

201

3; 1

3(12

); 10

50-1

056.

2.

van

Loo

n FP

L, C

lem

ens J

D, C

hakr

abor

ty M

R et

al.

Fiel

d tr

ial o

f ina

ctiv

ated

ora

l cho

lera

vac

cine

s in

Bang

lade

sh: r

esul

ts fr

om 5

yea

rs o

f fol

low

-up.

Vac

cine

199

6; 1

4(2)

: 162

-166

.